Select publications

Baum M et al; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract

Burstein HJ. Beyond tamoxifen—Extending endocrine treatment for early-stage breast cancer. N Engl J Med 2003;349(19):1857-9. No abstract available

Buzdar AU et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. ASCO, 2004;Abstract 520.

Coombes C et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Dowsett M, on behalf of the ATAC Trialists Group. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82(1 Suppl 1):6. Abstract 4

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract

Paik S et al. Real-world performance of HER2 testing — National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94(11):852-4. Abstract

Roche PC et al. Concordance between local and central laboratory HER2 testing in the breast Intergroup trial N9831. J Natl Cancer Inst 2002;94(11):855-7. Abstract